Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 7.9%

Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) fell 7.9% on Wednesday . The stock traded as low as $0.50 and last traded at $0.51. 187,369 shares traded hands during trading, a decline of 87% from the average session volume of 1,417,318 shares. The stock had previously closed at $0.55.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating on shares of Kiora Pharmaceuticals in a research note on Wednesday, March 27th.

Kiora Pharmaceuticals Stock Performance

The company has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $0.59.

Institutional Trading of Kiora Pharmaceuticals

Several large investors have recently added to or reduced their stakes in KPRX. Boothbay Fund Management LLC purchased a new stake in Kiora Pharmaceuticals during the 4th quarter valued at about $40,000. Dimensional Fund Advisors LP acquired a new position in shares of Kiora Pharmaceuticals in the 1st quarter valued at about $41,000. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals in the 4th quarter valued at about $49,000. Renaissance Technologies LLC acquired a new position in shares of Kiora Pharmaceuticals in the 1st quarter valued at about $58,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Kiora Pharmaceuticals in the 1st quarter valued at about $70,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.